Armodafinil in the treatment of excessive sleepiness

Bogan, Richard

doi:10.1517/14656561003705738

Cited by 15 publications

(6 citation statements)

References 74 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Armodafinil, the R-isomer of modafinil, has been shown to be effective against daytime somnolence [78], and both modafinil and armodafinil have been used to treat fatigue [67,73,79]. To better evaluate this possible mechanism of action, a followup study was performed using the agent armodafinil in sarcoidosis-associated fatigue patients [70].…”

Section: Treatment Of Fatigue With Neurostimulantsmentioning

confidence: 99%

Sarcoidosis-associated fatigue

Drent¹,

Lower²,

Vries³

2012

Eur Respir J

202

182

View full text Add to dashboard Cite

Sarcoidosis-associated fatigue is globally recognised as a disabling symptom. Fatigue has been reported in up to 50-70% of sarcoidosis patients, causing impaired quality of life. The aetiology of this troublesome problem remains elusive and is usually multifactorial. Fatigue can be a consequence of treatment itself, including as a complication of corticosteroid therapy. The diagnosis of sarcoidosis-associated fatigue requires an extensive evaluation to identify and treat potentially reversible causes. Granuloma formation and cytokine release may be involved in its aetiology. However, despite adequate sarcoidosis treatment, many patients continue to experience fatigue. Comorbidities associated with sarcoidosis, including depression, anxiety, hypothyroidism and altered sleep patterns, may all contribute to fatigue. Despite an exhaustive search for treatable clinical causes of fatigue, most patients' complaints of fatigue are not correlated with clinical parameters of disease activity. Recent studies have demonstrated the effectiveness of various neurostimulants, including methylphenidate, for the treatment of sarcoidosis-associated fatigue. These and other agents may be useful adjuncts for the treatment of sarcoidosis-associated fatigue. Obviously, there is a need for studies evaluating the causes and new therapeutic options of sarcoidosis-associated fatigue. Psychological interventions should also be examined.

show abstract

Section: Treatment Of Fatigue With Neurostimulantsmentioning

confidence: 99%

Sarcoidosis-associated fatigue

Drent¹,

Lower²,

Vries³

2012

Eur Respir J

202

182

View full text Add to dashboard Cite

show abstract

“…The orexin system plays an important role in the regulation of sleep and wakefulness, especially in the maintenance of sustained wakefulness . Modafinil and armodafinil are drugs that potentially agonize this system and are indicated for promoting wakefulness in narcolepsy, apnea, and shift work patients [34,35]. Orexin neurons link the ventrolateral preoptic area and the brainstem’s reticular activating system’s wakefulness-promoting nuclei (serotonin, norepinephrine, and dopamine).…”

Section: Contemporary Treatment Of Insomniamentioning

confidence: 99%

Managing insomnia: an overview of insomnia and pharmacologic treatment strategies in use and on the horizon

Schwartz¹,

Goradia²

2013

DIC

View full text Add to dashboard Cite

This review explores basic sleep physiology, the mechanism of action for each class of hypnotic agents, their clinical application based on pharmacodynamic and pharmacokinetic factors, and potential pharmacologic sleep-inducing mechanisms of future hypnotics. The paper challenges the reader to understand the neuroscientific basis of insomnia and use this knowledge to guide prescription of hypnotic agents.Currently indicated hypnotic agents are discussed with regard to their mechanism of drug action and clinical application. A broader discussion is developed throughout this paper regarding other non-indicated agents that may improve sleep and describing newer pharmacological treatments that may become available in the future for use in sleep disorders and their comorbid conditions.

show abstract

“…Because of this difference, armodafinil has less plasma drug variability and is more effective in promoting wakefulness toward the end of an 8-hour shift in patients with SWD. [45][46][47] Both modafinil and armodafinil have been shown to immediately reduce daytime sleepiness and improve cognitive performance; however, optimization can take several days. 48 Side effects of modafinil and armodafinil include headache, nausea, dizziness, and insomnia; however, these agents have less risk of causing anxiety, jitteriness, and rebound effects compared to traditional stimulants.…”

Section: Modafinil and Armodafinilmentioning

confidence: 99%

Twisting the night away: a review of the neurobiology, genetics, diagnosis, and treatment of shift work disorder

Morrissette

2013

CNS Spectr.

View full text Add to dashboard Cite

Although not all individuals who work outside of standard daytime hours develop physical and psychiatric issues, there is a substantial portion of shift workers who develop shift work disorder. Shift work disorder is due to a misalignment between an individual's endogenous circadian rhythms and environmental stimuli, and can have potentially serious consequences to an individual's health and quality of life. This article reviews the neurobiological and genetic underpinnings of shift work disorder, and describes how desynchronization of the molecular clock may lead to both physical and psychiatric illnesses. Diagnostic tools and treatment guidelines to address the circadian misalignment, excessive sleepiness, and insomnia experienced by patients with shift work disorder are also discussed.

show abstract

Armodafinil in the treatment of excessive sleepiness

Cited by 15 publications

References 74 publications

Sarcoidosis-associated fatigue

Sarcoidosis-associated fatigue

Managing insomnia: an overview of insomnia and pharmacologic treatment strategies in use and on the horizon

Twisting the night away: a review of the neurobiology, genetics, diagnosis, and treatment of shift work disorder

Contact Info

Product

Resources

About